RU2003119545A - PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF PHAMACOLOGICAL ACTIVE SUBSTANCES - Google Patents

PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF PHAMACOLOGICAL ACTIVE SUBSTANCES

Info

Publication number
RU2003119545A
RU2003119545A RU2003119545/15A RU2003119545A RU2003119545A RU 2003119545 A RU2003119545 A RU 2003119545A RU 2003119545/15 A RU2003119545/15 A RU 2003119545/15A RU 2003119545 A RU2003119545 A RU 2003119545A RU 2003119545 A RU2003119545 A RU 2003119545A
Authority
RU
Russia
Prior art keywords
composition according
active substance
preceding paragraphs
calcitonin
oral administration
Prior art date
Application number
RU2003119545/15A
Other languages
Russian (ru)
Other versions
RU2287999C2 (en
Inventor
Джозеф М. ОЛТ
Мойзе АЗРИЯ
Саймон Дейвид БЕЙТМАН
Джозеф СИКОРА
Грегори СПАРТА
Ребекка Файин ЯН
Дзе СЯО
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2003119545A publication Critical patent/RU2003119545A/en
Application granted granted Critical
Publication of RU2287999C2 publication Critical patent/RU2287999C2/en

Links

Claims (14)

1. Твердая фармацевтическая композиция для перорального введения фармакологического действующего вещества, содержащая:1. A solid pharmaceutical composition for oral administration of a pharmacologically active substance, comprising: а) терапевтически эффективное количество фармакологического действующего вещества;a) a therapeutically effective amount of a pharmacological active substance; б) кросповидон или повидон; иb) crospovidone or povidone; and в) агент, способствующий введению указанного фармакологического действующего вещества.C) an agent that promotes the introduction of the specified pharmacological active substance. 2. Композиция по п.1, где действующее вещество представляет собой пептид.2. The composition according to claim 1, where the active substance is a peptide. 3. Композиция по п.1 где пептид представляет собой кальцитонин.3. The composition of claim 1, wherein the peptide is calcitonin. 4. Композиция по п.3, где кальцитонин представляет собой кальцитонин лосося.4. The composition according to claim 3, where calcitonin is a salmon calcitonin. 5. Композиция по любому из предыдущих пунктов, содержащая кросповидон.5. The composition according to any one of the preceding paragraphs, containing crospovidone. 6. Композиция по любому из предыдущих пунктов, где способствующий введению агент представляет собой 5-CNAC.6. The composition according to any one of the preceding paragraphs, where the facilitating the introduction of the agent is 5-CNAC. 7. Композиция по любому из предыдущих пунктов, где способствующий введению агент представляет собой двунатриевую соль 5-CNAC.7. The composition according to any one of the preceding paragraphs, where the facilitating the introduction of the agent is a disodium salt of 5-CNAC. 8. Композиция по любому из предыдущих пунктов, которая дополнительно содержит разбавитель.8. The composition according to any one of the preceding paragraphs, which further comprises a diluent. 9. Композиция по п.8, где разбавитель представляет собой микрокристаллическую целлюлозу.9. The composition of claim 8, where the diluent is microcrystalline cellulose. 10. Композиция по п.1, которая дополнительно содержит замасливатель.10. The composition according to claim 1, which further comprises a sizing. 11. Композиция по любому из предыдущих пунктов, где замасливатель представляет собой стеарат магния.11. The composition according to any one of the preceding paragraphs, where the sizing is magnesium stearate. 12. Способ повышения биологической доступности фармакологического действующего вещества при пероральном введении, который заключается во введении пациенту, нуждающемуся в применении фармакологического действующего вещества, эффективного количества фармацевтической композиции по любому из предыдущих пунктов.12. A method of increasing the bioavailability of a pharmacologically active substance when administered orally, which consists in administering to a patient in need of a pharmacological active substance an effective amount of a pharmaceutical composition according to any one of the preceding paragraphs. 13. Способ лечения заболеваний кости и связанных с кальцием нарушений, который заключается во введении пациенту, нуждающемуся в таком лечении, терапевтически эффективного количества композиции по любому из п.п.1-11, где фармакологическое действующее вещество представляет собой кальцитонин.13. A method of treating bone diseases and calcium-related disorders, which consists in administering to a patient in need of such treatment a therapeutically effective amount of a composition according to any one of claims 1 to 11, wherein the pharmacologically active substance is calcitonin. 14. Способ по п.13, где кальцитонин представляет собой кальцитонин лосося.14. The method of claim 13, wherein the calcitonin is salmon calcitonin.
RU2003119545/15A 2000-12-06 2001-12-05 Pharmaceutical compositions for peroral intake of pharmacological active substances RU2287999C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25172900P 2000-12-06 2000-12-06
US60/251,729 2000-12-06

Publications (2)

Publication Number Publication Date
RU2003119545A true RU2003119545A (en) 2004-12-27
RU2287999C2 RU2287999C2 (en) 2006-11-27

Family

ID=22953160

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003119545/15A RU2287999C2 (en) 2000-12-06 2001-12-05 Pharmaceutical compositions for peroral intake of pharmacological active substances

Country Status (27)

Country Link
US (1) US7049283B2 (en)
EP (1) EP1341526B1 (en)
JP (2) JP4898078B2 (en)
KR (1) KR100847695B1 (en)
CN (1) CN1304048C (en)
AT (1) ATE513541T1 (en)
AU (2) AU3454702A (en)
BR (2) BRPI0115965B1 (en)
CA (1) CA2436599C (en)
CY (1) CY1112562T1 (en)
CZ (1) CZ305418B6 (en)
DK (1) DK1341526T3 (en)
EC (1) ECSP034639A (en)
ES (1) ES2367009T3 (en)
HK (1) HK1059565A1 (en)
HU (1) HU230632B1 (en)
IL (2) IL155992A0 (en)
MX (1) MXPA03005096A (en)
NO (1) NO332936B1 (en)
NZ (1) NZ526196A (en)
PL (1) PL209703B1 (en)
PT (1) PT1341526E (en)
RU (1) RU2287999C2 (en)
SI (1) SI1341526T1 (en)
SK (1) SK287613B6 (en)
WO (1) WO2002045754A2 (en)
ZA (1) ZA200304295B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2235854T3 (en) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. DISODIC SALTS, MONOHIDRATES AND ETHANOL SOLVATES TO CONTRIBUTE ACTIVE AGENTS.
CZ307145B6 (en) * 2001-06-01 2018-02-07 Novartis Ag A composition for oral administration, the use of this composition and a kit for stimulation of new bone formation
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
PE20040724A1 (en) * 2002-08-01 2004-12-06 Novartis Ag COMPOSITION FOR THE ORAL ADMINISTRATION OF CALCITONIN
MXPA05009848A (en) * 2003-03-17 2005-12-06 Japan Tobacco Inc Pharmaceutical compositions of cetp inhibitors.
TWI494102B (en) * 2003-05-02 2015-08-01 Japan Tobacco Inc Combination comprising s-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino)phenyl)2-methylpropanethioate and an hmg coa reductase inhibitor
DE602004023093D1 (en) * 2003-07-11 2009-10-22 Novartis Ag N WITH A DISPENSER IN MICRONIZED FORM
PL3395338T3 (en) * 2003-09-12 2019-10-31 Amgen Inc Rapid dissolution formulation of cinacalcet hcl
NZ588373A (en) * 2004-05-19 2012-01-12 Emisphere Tech Inc Topical cromolyn formulations
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
US20080153779A1 (en) * 2005-02-01 2008-06-26 Jun Liao Gastric Retention and Controlled Release Delivery System
WO2007005995A2 (en) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
US8026392B2 (en) 2005-09-19 2011-09-27 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-Chlorosalicyloyl)-8-aminocaprylic acid
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
WO2007061829A2 (en) * 2005-11-17 2007-05-31 Novartis Ag Pharmaceutical composition
CA2642761A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
WO2008021088A2 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
AU2007289344B2 (en) * 2006-08-31 2011-04-14 Novartis Ag Pharmaceutical compositions comprising hGH for oral delivery
CA2572004A1 (en) * 2006-12-08 2008-06-08 Bernard Charles Sherman Tablets comprising entacapone and crospovidone
DE602008006700D1 (en) * 2007-03-02 2011-06-16 Novartis Ag
JP5555634B2 (en) 2007-11-02 2014-07-23 エミスフェア テクノロジーズ インコーポレイティッド Method for treating vitamin B12 deficiency
US9186412B2 (en) * 2008-08-18 2015-11-17 Entera Bio Ltd. Methods and compositions for oral administration of insulin
NZ595021A (en) * 2009-03-12 2013-04-26 Nordic Bioscience As Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists
KR101811376B1 (en) * 2010-06-09 2017-12-22 에미스페어 테크놀로지스, 인코포레이티드 Oral iron deficiency therapy
PL2651398T3 (en) 2010-12-16 2018-05-30 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN103619175B (en) 2011-04-12 2016-08-17 诺沃—诺迪斯克有限公司 Double acylated GLP-1 derivants
HRP20231060T1 (en) 2012-03-22 2023-12-22 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
TR201903918T4 (en) 2012-03-22 2019-04-22 Novo Nordisk As Compositions containing a dispersing agent and their preparation.
JP6356660B2 (en) 2012-03-22 2018-07-11 ノヴォ ノルディスク アー／エス Compositions containing delivery agents and their preparation
CN104487056A (en) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） Tablet formulation comprising a peptide and a delivery agent
CN104961687B (en) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2 diazine derivatives and its preparation, purposes
CN115368438A (en) * 2015-07-08 2022-11-22 成均馆大学校产学协力团 Pyrrolidine amide derivatives and methods of making and using the same
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
CN107080739A (en) * 2017-04-17 2017-08-22 深圳市泛谷药业股份有限公司 A kind of solid quick release blonanserin piece for being used to be administered orally and preparation method thereof
EP3746111B1 (en) 2018-02-02 2023-07-19 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
JP2021054781A (en) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド Co-crystalline efinaconazole and method for producing the same
KR102301743B1 (en) * 2020-12-29 2021-09-13 대봉엘에스 주식회사 Oral pharmaceutical composition comprsing efinaconazole

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015633A (en) 1987-04-27 1991-05-14 E. R. Squibb & Sons, Inc. Method for inhibiting loss of cognitive functions employing an ace inhibitor
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5002771A (en) 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
IT1238072B (en) 1990-01-19 1993-07-03 Sclavo Spa PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ORAL ADMINISTRATION OF CALCITONIN
JPH052771A (en) * 1991-06-25 1993-01-08 Pioneer Electron Corp Optical recording medium
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
ES2154744T3 (en) 1994-12-14 2001-04-16 Enbalt Trading Ltd FORMULATIONS OF PHARMACEUTICAL TABLETS FOR DIRECT COMPRESSION.
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (en) * 1995-03-31 1998-05-19 Emisphere Tech Inc Compound composition dosage unit form methods for administering a biologically active agent for preparing a composition for administering an active agent and for preparing a compound and pharmacological composition
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5958453A (en) 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2319672C (en) 1997-02-07 2011-01-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL138153A0 (en) 1998-03-16 2001-10-31 Inhale Therapeutic Syst Methods and devices for delivering aerosolized active agents
AU3574500A (en) 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
ES2235854T3 (en) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. DISODIC SALTS, MONOHIDRATES AND ETHANOL SOLVATES TO CONTRIBUTE ACTIVE AGENTS.
WO2000059480A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making

Similar Documents

Publication Publication Date Title
RU2003119545A (en) PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF PHAMACOLOGICAL ACTIVE SUBSTANCES
CA2436599A1 (en) Oral pharmaceutical compositions comprising polyvinylpyrrolidone (pvp) and 5-cnac
RU2136281C1 (en) Oral liquid pharmaceutical composition containing complex of paroxitine and amberlite irp-88 and method of treatment using this composition
RU2000100361A (en) SODIUM SALT OMEGRAZOLE
RU98111594A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING FLURBIPROFEN
BR0011867A (en) Pharmaceutical preparation of levodopa / carbidopa / entacapone
RU94027680A (en) Parathyroid hormone and raloxifen for bone mass increase, pharmaceutical composition and method of osseous mass increase
RU2006109467A (en) METHODS FOR TREATING CANCER USING HDAC INHIBITORS
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
RU2006105479A (en) APPLICATION OF CALCITONIN IN OSTEOARTHRITIS
ATE235895T1 (en) DRUG DELIVERY SYSTEM CONTAINING A HARD-PACKED, SOLID DRUG BASE
CO4600739A1 (en) ALENDRONATE BASED ORAL LIQUID FORMULATIONS
RU2004129324A (en) APPLICATIONS OF BISPHOSPHONIC ACIDS FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS
RU2153337C2 (en) Paracetamol and domperidone tablet with film coating
CA2529604A1 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
RU2001119054A (en) Potassium salt of (S) -omeprazole
SE8306367L (en) ANTIDIURETICALLY EFFECTIVE PHARMACEUTICAL PREPARATION
RU2006139819A (en) APPLICATION OF SYMETICON FOR PATIENTS POSITIONED FOR CONSTIPATION
RU2006115784A (en) The use of L-butylphthalide for the manufacture of a medicament for the prevention and treatment of cerebral infarction
RU2005105691A (en) Oral Administration of Calcitonin
RU97120700A (en) NEW PHARMACOLOGICAL APPLICATION OF ANTAGONISTS A-II RECEPTOR
MA27157A1 (en) METHOD FOR THE TREATMENT OF BONE CONDITIONS.
CA2480275A1 (en) Statin therapy for enhancing cognitive maintenance
CA2368352A1 (en) Method for treating neurodegeneration
KR20010105418A (en) Osanetant in the Treatment of Mood Disorders